Literature DB >> 21732673

A single mutation in arrestin-2 prevents ERK1/2 activation by reducing c-Raf1 binding.

Sergio Coffa1, Maya Breitman, Benjamin W Spiller, Vsevolod V Gurevich.   

Abstract

Arrestins regulate the signaling and trafficking of G protein-coupled receptors (GPCRs). GPCR complexes with both nonvisual arrestins channel signaling to G protein-independent pathways, one of which is the activation of extracellular signal regulated kinase 1/2 (ERK1/2). Here we used alanine-scanning mutagenesis of residues on the nonreceptor-binding surface conserved between arrestin-2 and arrestin-3. We show that an Arg307Ala mutation significantly reduced arrestin-2 binding to c-Raf1, whereas the binding of the mutant to active phosphorylated receptor and downstream kinases MEK1 and ERK2 was not affected. In contrast to wild-type arrestin-2, the Arg307Ala mutant failed to rescue arrestin-dependent ERK1/2 activation via β2-adrenergic receptor in arrestin-2/3 double knockout mouse embryonic fibroblasts. Thus, Arg307 plays a specific role in arrestin-2 binding to c-Raf1 and is indispensable in the productive scaffolding of c-Raf1-MEK1-ERK1/2 signaling cascade. Arg307Ala mutation specifically eliminates arrestin-2 signaling through ERK, which makes arrestin-2-Arg307Ala the first signaling-biased arrestin mutant constructed. In the crystal structure the side chain of homologous arrestin-3 residue Lys308 points in a different direction. Alanine substitution of Lys308 does not significantly affect c-Raf1 binding to arrestin-3 and its ability to promote ERK1/2 activation, suggesting that the two nonvisual arrestins perform the same function via distinct molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21732673      PMCID: PMC3153575          DOI: 10.1021/bi200745k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  54 in total

1.  Mapping the arrestin-receptor interface. Structural elements responsible for receptor specificity of arrestin proteins.

Authors:  Sergey A Vishnivetskiy; M Marlene Hosey; Jeffrey L Benovic; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2003-10-06       Impact factor: 5.157

Review 2.  G-protein-coupled receptors: turn-ons and turn-offs.

Authors:  C V Carman; J L Benovic
Journal:  Curr Opin Neurobiol       Date:  1998-06       Impact factor: 6.627

3.  The selectivity of visual arrestin for light-activated phosphorhodopsin is controlled by multiple nonredundant mechanisms.

Authors:  V V Gurevich
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

4.  Use of bacteriophage RNA polymerase in RNA synthesis.

Authors:  V V Gurevich
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

5.  The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis.

Authors:  S A Laporte; R H Oakley; J Zhang; J A Holt; S S Ferguson; M G Caron; L S Barak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Visual arrestin binding to rhodopsin. Diverse functional roles of positively charged residues within the phosphorylation-recognition region of arrestin.

Authors:  V V Gurevich; J L Benovic
Journal:  J Biol Chem       Date:  1995-03-17       Impact factor: 5.157

7.  Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells.

Authors:  A Kovoor; J Celver; R I Abdryashitov; C Chavkin; V V Gurevich
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

8.  Topographic study of arrestin using differential chemical modifications and hydrogen/deuterium exchange.

Authors:  H Ohguro; K Palczewski; K A Walsh; R S Johnson
Journal:  Protein Sci       Date:  1994-12       Impact factor: 6.725

9.  Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor.

Authors:  O B Goodman; J G Krupnick; F Santini; V V Gurevich; R B Penn; A W Gagnon; J H Keen; J L Benovic
Journal:  Nature       Date:  1996-10-03       Impact factor: 49.962

10.  Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2-adrenergic, and m2 muscarinic cholinergic receptors.

Authors:  V V Gurevich; S B Dion; J J Onorato; J Ptasienski; C M Kim; R Sterne-Marr; M M Hosey; J L Benovic
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

View more
  43 in total

Review 1.  Synthetic biology with surgical precision: targeted reengineering of signaling proteins.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Cell Signal       Date:  2012-06-01       Impact factor: 4.315

Review 2.  Extensive shape shifting underlies functional versatility of arrestins.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Curr Opin Cell Biol       Date:  2013-11-16       Impact factor: 8.382

Review 3.  Plethora of functions packed into 45 kDa arrestins: biological implications and possible therapeutic strategies.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Cell Mol Life Sci       Date:  2019-08-17       Impact factor: 9.261

Review 4.  The Diverse Roles of Arrestin Scaffolds in G Protein-Coupled Receptor Signaling.

Authors:  Yuri K Peterson; Louis M Luttrell
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

5.  Engineering visual arrestin-1 with special functional characteristics.

Authors:  Sergey A Vishnivetskiy; Qiuyan Chen; Maria C Palazzo; Evan K Brooks; Christian Altenbach; Tina M Iverson; Wayne L Hubbell; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 6.  The structural basis of the arrestin binding to GPCRs.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Mol Cell Endocrinol       Date:  2019-01-28       Impact factor: 4.102

7.  Arrestin-dependent activation of JNK family kinases.

Authors:  Xuanzhi Zhan; Seunghyi Kook; Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

8.  Targeting individual GPCRs with redesigned nonvisual arrestins.

Authors:  Luis E Gimenez; Sergey A Vishnivetskiy; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

9.  Therapeutic potential of small molecules and engineered proteins.

Authors:  Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

10.  Self-association of arrestin family members.

Authors:  Qiuyan Chen; Ya Zhuo; Miyeon Kim; Susan M Hanson; Derek J Francis; Sergey A Vishnivetskiy; Christian Altenbach; Candice S Klug; Wayne L Hubbell; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.